Evidence-based data support prevention strategies to Hymenoptera venom anaphylaxis.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
23 Jul 2024
23 Jul 2024
Historique:
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
aheadofprint
Résumé
This review aims to identify phenotypes at-risk of Hymenoptera venom-induced anaphylaxis (HVA), focusing on different perspectives (epidemiological, clinical, and therapeutic) in order to adapt future preventive strategies. HVA remains one of the leading causes of anaphylaxis, with a broad pattern of symptoms. Although most cases occur outside healthcare settings, data indicate a high emergency admission rate due to insect stings. Mortality is often underestimated because of the lack of witnesses and difficulties in recognizing the signs and the culprit. Targeting risk factors could be a clue to improve these statistics and the prognosis of the disease.Potential risk factors for severe HVA in the European population are basal serum tryptase (BST) above 8 μg, mast cell disorders, the absence of skin symptoms, and cardiovascular conditions requiring the use of beta blockers and ACE inhibitors. Identifying these criteria, mainly based on clinical patterns, helps to develop personalized strategies for management and prevention. With a personalized medicine approach, phenotypes must be characterized to adapt to the management of patients suffering from Hymenoptera venom anaphylaxis (HVA), including venom immunotherapy (VIT). In this systematic review, all articles mentioned systemic reactions with heterogeneous severity degrees. Half of those reported grade III-IV systemic reactions (Ring and Messmer). HVA clinical patterns could be worsened by one Hymenoptera sting, a patient's history with mast cell disorders, or cardiovascular diseases. VIT failure was attributed to bee venom extract and monotherapy in two-thirds of publications. Findings stress the difficulty of having uniform epidemiological data on HVA and the lack of financial support in some world regions to support appropriate management of these conditions. Although observing a heterogeneity of data, we were able to identify potential risk factors, in particular for the severe cases. We believe our work will support allergists and health professionals to implement improved personalized management of patients suffering from severe HVA.
Identifiants
pubmed: 39052760
doi: 10.1097/ACI.0000000000001011
pii: 00130832-990000000-00138
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Bilò MB, Pravettoni V, Bignardi D, et al. Hymenoptera venom allergy: management of children and adults in clinical practice. J Investig Allergol Clin Immunol 2019; 29:180–205.
Worm M, Moneret-Vautrin A, Scherer K, et al. First European data from the network of severe allergic reactions (NORA). Allergy 2014; 69:1397–1404.
Clark S, Long AA, Gaeta TJ, Camargo CA. Multicenter study of emergency department visits for insect sting allergies. J Allergy Clin Immunol 2005; 116:643–649.
Bilò MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy 2009; 39:1467–1476.
Stoevesandt J, Sturm GJ, Bonadonna P, et al. Risk factors and indicators of severe systemic insect sting reactions. Allergy 2020; 75:535–545.
Bilò MB, Corsi A, Martini M, et al. Fatal anaphylaxis in Italy: analysis of cause-of-death national data, 2004-2016. Allergy 2020; 75:2644–2652.
Mosbech H. Death caused by wasp and bee stings in Denmark 1960–1980. Allergy 1983; 38:195–200.
Harvey P, SpWOerber S, Kette F, et al. Bee-sting mortality in Australia. Med J Aust 1984; 140:209–211.
Clifford D, Ni Chaoimh C, Stanley E, O’B. Hourihane J. A longitudinal study of hymenoptera stings in preschool children. Pediatr Allergy Immunol 2019; 30:93–98.
Fernandez J, Blanca M, Soriano V, et al. Epidemiological study of the prevalence of allergic reactions to Hymenoptera in a rural population in the Mediterranean area. Clin Exp Allergy 1999; 29:1069–1074.
Fernandez J, Soriano V, Mayorga L, Mayor M. Natural history of Hymenoptera venom allergy in Eastern Spain. Clin Exp Allergy 2005; 35:179–185.
Schuler CF, Volertas S, Khokhar D, et al. Prevalence of mastocytosis and Hymenoptera venom allergy in the United States. J Allergy Clin Immunol 2021; 148:1316–1323.
Mingomataj E, Priftanji A, Qirko E, et al. Specific immunotherapy in Albanian patients with anaphylaxis to Hymenoptera venoms. BMC Dermatol 2002; 2:11.
Visitsunthorn N, Kijmassuwan T, Visitsunthorn K, et al. Clinical characteristics of allergy to Hymenoptera stings. Pediatr Emerg Care 2019; 35:600–604.
Gelincik A, İşsever H, Unal D, et al. The prevalence of Hymenoptera venom allergy in adults: the results of a very crowded city in Euroasia. Allergol Int 2015; 64:35–40.
Srisuwarn P, Srisuma S, Sriapha C, et al. Clinical effects, and factors associated with adverse clinical outcomes of hymenopteran stings treated in a Thai Poison Centre: a retrospective cross-sectional study. Clin Toxicol (Phila) 2022; 60:168–174.
Witharana EWRA, Wijesinghe SKJ, Pradeepa KSM, et al. Bee and wasp stings in Deniyaya; a series of 322 cases. Ceylon Med J 2015; 60:5–9.
Kularatne SAM, Shahmy S, Rathnayake SS, Dawson AH. Clinical epidemiology of arthropod stings and bites in primary hospitals of Northwestern province of Sri Lanka. Clin Toxicol (Phila) 2018; 56:880–885.
Pérez-Pimiento AJ, González-Sánchez LA, Alonso-González L, et al. Anaphylaxis to hymenoptera sting: study of 113 patients. Med Clin (Barc) 2005; 125:417–420.
Schoeben LS, Bubak C, Schaarschmidt ML, Schmieder A. Sex differences in adults with insect venom allergy regarding psychological distress, attitudes toward the emergency medication, and factual knowledge about the disease. Int Arch Allergy Immunol 2020; 181:529–535.
Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047–1054.
Potier A, Lavigne C, Chappard D, et al. Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase. Clin Exp Allergy 2009; 39:717–725.
Schultze-Werninghaus C, Wahn U, Niggemann B. Evaluation of the risk of anaphylactic reactions by wasp venom-extract challenges in children. Pediatr Allergy Immunol 1999; 10:133–137.
Rancé F, Abbal M, Brémont F, Dutau G. Allergy to Hymenoptera venoms in children. Arch Pediatr 1999; 6: (Suppl 1): 55S–60S.
Bilò MB, Martini M, Pravettoni V, et al. Large local reactions to Hymenoptera stings: outcome of re-stings in real life. Allergy 2019; 74:1969–1976.
Nittner-Marszalska M, Liebhart J, Dor-Wojnarowska A. Sex-related clinical aspects in insect venom anaphylaxis. Int J Immunopathol Pharmacol 2015; 28:187–193.
Pucci S, D’Alò S, De Pasquale T, et al. Risk of anaphylaxis in patients with large local reactions to Hymenoptera stings: a retrospective and prospective study. Clin Mol Allergy 2015; 13:21.
Temperville R, Gaouar H, Autegarden JE, et al. Réactions allergiques IgE-médiées aux venins d’hyménoptères et tolérance de l’immunothérapie spécifique chez les adultes atteints de mastocytose. Revue Française d’Allergologie 2019; 59:259.
Antonicelli L, Bilò MB, Napoli G, et al. European hornet (Vespa crabro) sting: a new risk factor for life-threatening reaction in hymenoptera allergic patients? Eur Ann Allergy Clin Immunol 2003; 35:199–203.
Lang R, Hawranek T. Hymenoptera venom immunotherapy and field stings. J Investig Allergol Clin Immunol 2006; 16:224–231.
Van der Linden PW, Hack CE, Struyvenberg A, van der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol 1994; 94 (2 Pt 1):151–159.
Chapsa M, Roensch H, Langner M, et al. Predictors of severe anaphylaxis in Hymenoptera venom allergy: the importance of absence of urticaria and angioedema. Ann Allergy Asthma Immunol 2020; 125:72–77.
Bonadonna P, Zanotti R, Pagani M, et al. Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected. J Allergy Clin Immunol Pract 2018; 6:1368–1372.
Fehr D, Micaletto S, Moehr T, Schmid-Grendelmeier P. Risk factors for severe systemic sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients. Clin Transl Allergy 2019; 9:54.
Karagol HIE, Bakirtas A, Yilmaz O, et al. Comparison of moderate to severe systemic reactions with honeybee and wasp in children. Int Forum Allergy Rhinol 2014; 4:548–554.
Westall GP, Thien FC, Czarny D, et al. Adverse events associated with rush hymenoptera venom immunotherapy. Med J Aust 2001; 174:227–230.
Konstantinou GN, Manoussakis E, Douladiris N, et al. A 5-year venom immunotherapy protocol with 50 (g maintenance dose: safety and efficacy in school children. Pediatr Allergy Immunol 2011; 22:393–397.
Golden DB, Kwiterovich KA, Kagey-Sobotka A, et al. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996; 97:579–587.
González de Olano D, Alvarez-Twose I, Esteban-López MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008; 121:519–526.
Stoevesandt J, Hosp C, Kerstan A, Trautmann A. Risk stratification of systemic allergic reactions during Hymenoptera venom immunotherapy buildup phase. J Dtsch Dermatol Ges 2014; 12:244–255.
Stritzke AI, Eng PA. Age-dependent sting recurrence and outcome in immunotherapy-treated children with anaphylaxis to Hymenoptera venom. Clin Exp Allergy 2013; 43:950–955.
Wenzel J, Meissner-Kraemer M, Bauer R, et al. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Allergy 2003; 58:1176–1179.
Stoevesandt J, Hofmann B, Hain J, et al. Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom. Allergy Asthma Clin Immunol 2013; 9:33.
Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy 2018; 73:744–764.
Ruëff F, Przybilla B, Biló MB, et al. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. PLoS One 2013; 8:e63233.
Hirata H, Asakura T, Arima M, et al. Efficacy and safety of rush immunotherapy in patients with Hymenoptera allergy in Japan. Asian Pac J Allergy Immunol 2003; 21:89–94.
van Halteren HK, van der Linden PW, Burgers JA, Bartelink AK. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 1997; 100 (6 Pt 1):767–770.
Adelmeyer J, Pickert J, Pfützner W, Möbs C. Long-term impact of hymenoptera venom immunotherapy on clinical course, immune parameters, and psychosocial aspects. Allergol Select 2021; 5:57–66.
Schwartz HJ, Golden DB, Lockey RF. Venom immunotherapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol 1990; 85:709–712.
Ruëff F, Vos B, Oude Elberink J, et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clin Exp Allergy 2014; 44:736–746.
Hafner T, DuBuske L, Kosnik M. Long-term efficacy of venom immunotherapy. Ann Allergy Asthma Immunol 2008; 100:162–165.
Bemanian MH, Farhoudi A, Pourpak Z, et al. Systemic and local reactions of bee venom immunotherapy in Iran. Iran J Allergy Asthma Immunol 2007; 6:203–206.
Gorska L, Chelminska M, Kuziemski K, et al. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Int Arch Allergy Immunol 2008; 147:241–245.
Pasaoglu G, Sin BA, Misirligil Z. Rush hymenoptera venom immunotherapy is efficacious and safe. J Investig Allergol Clin Immunol 2006; 16:232–238.
Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993; 23:226–230.
Laurent J, Smiejan JM, Bloch-Morot E, Herman D. Safety of Hymenoptera venom rush immunotherapy. Allergy 1997; 52:94–96.
Fiedler C, Miehe U, Treudler R, et al. Long-term follow-up of children after venom immunotherapy: low adherence to anaphylaxis guidelines. Int Arch Allergy Immunol 2017; 172:167–172.
Tanno LK, Ganem F, Demoly P, et al. Undernotification of anaphylaxis deaths in Brazil due to difficult coding under the ICD-10. Allergy 2012; 67:783–789.
Leung ASY, Pawankar R, Pacharn P, et al. Asia Pacific Association of Allergy Asthma and Clinical Immunology food allergy and anaphylaxis and junior member committees Perspectives and gaps in the management of food allergy and anaphylaxis in the Asia-Pacific Region. J Allergy Clin Immunol Glob 2024; 3:100202.
Goldberg A, Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy Asthma Immunol 2003; 91:405–410.
Charpin D, Birnbaum J, Vervloet D. Epidemiology of hymenoptera allergy. Revue Française d’Allergologie et d’Immunologie Clinique 1995; 35:396–402.
Quan PL, Sabaté-Brescó M, Guo Y, et al. The multifaceted mas-related G protein-coupled receptor member X2 in allergic diseases and beyond. Int J Mol Sci 2021; 22:4421.
Elst J, De Puysseleyr LP, Ebo DG, et al. Overexpression of FcεRI on bone marrow mast cells, but not MRGPRX2, in clonal mast cell disorders with wasp venom anaphylaxis. Front Immunol 2022; 13:835618.
Mosbech H, Müller U. Behalf Of The Study Group∗ O Side-effects of insect venom immunotherapy:results from an EAACI multicenter study. Allergy 2000; 55:1005–1010.
Ruëff F, Bauer A, Becker S, et al. Diagnosis and treatment of Hymenoptera venom allergy. Allergol Select 2023; 7:154–190.
Kalogeromitros D, Makris M, Gregoriou S, et al. Pattern of sensitization to honeybee venom in beekeepers: a 5-year prospective study. Allergy Asthma Proc 2006; 27:383–387.
Bonadonna P, Caruso B, Labardi D, et al. Treatment with American Polistes venom was ineffective in an Italian patient allergic to European Polistes. Allergy 2007; 62:966–967.
Bourrain JL, Van der Brempt X. Polistes Attack ! Est-ce qu’on y pense trop dans le sud et pas assez dans le nord ? Revue Française d’Allergologie 2024; 64:104062.
Grossi V, Severino M, Massolo A, et al. Vespa velutina nigrithorax venom allergy: inhibition studies approach for the choice of specific immunotherapy. Eur Ann Allergy Clin Immunol 2023; 55:161–165.